Qiagen launches H1N1 test globally
This article was originally published in Clinica
Executive Summary
Qiagen has launched its artus Influenza/H1 RG/LC RT-PCR Kit, designed to detect the H1N1 virus, worldwide. The test, which provides results in around 40 minutes, "currently has no official US FDA approval or CE marking", a spokesperson for Qiagen told Clinica. However, the firm is "evaluating its options and wouldn't exclude this possibility in the future". The first customer to order the test is the government of Saudi Arabia. Qiagen (Venlo, the Netherlands) claims the diagnostic can detect H1N1 and other influenza A and B strains. Other PCR-based tests can take up to 24 hours to carry out, but rapid, antibody-based tests have been criticised for lacking sensitivity.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.